Previous close | 6.76 |
Open | 6.73 |
Bid | 6.86 x 1400 |
Ask | 6.87 x 1800 |
Day's range | 6.57 - 6.91 |
52-week range | 4.68 - 19.22 |
Volume | |
Avg. volume | 4,652,728 |
Market cap | 382.312M |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.12 |
Earnings date | 13 Apr 2022 - 18 Apr 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 14 Oct 1999 |
1y target est | 3.00 |
Why Rite Aid's (NYSE: RAD) stock pop and raised guidance still aren't enough to get him interested in buying shares. Additionally, with shares down nearly 70% over the past year, is Zoom Video Communications (NASDAQ: ZM) a screaming buy or past its prime? To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.
Yahoo Finance Live anchors discuss third-quarter earnings for Walgreens.
PHILADELPHIA, June 30, 2022--Elixir, a wholly owned subsidiary of Rite Aid (NYSE: RAD), announced the launch of a specialty generic medication enhancement to its managed copay solutions effective June 1, 2022. The enhancement allows members to receive generic versions of certain specialty medications at a $0 copay and has the potential to provide an average savings of up to $40,000 annually.